{"classes":[{"categories":[{"measurements":[{"comment":"Median duration of OS was not reached due to insufficient follow-up. Upper limit of CI was not reached due to low number of participants with events.","groupId":"OG000","lowerLimit":"50.86","upperLimit":"NA","value":"NA"},{"groupId":"OG001","lowerLimit":"54.54","upperLimit":"67.98","value":"65.97"},{"comment":"Upper limit of CI was not reached due to low number of participants with events.","groupId":"OG002","lowerLimit":"48.23","upperLimit":"NA","value":"55.39"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"160"},{"groupId":"OG001","value":"165"},{"groupId":"OG002","value":"173"}],"units":"Participants"}],"description":"OS was defined as the time from randomization to death from any cause. Median duration of OS was estimated using Kaplan-Meier analysis.","dispersionType":"Full Range","groups":[{"description":"Participants received trastuzumab plus either docetaxel or paclitaxel. The regimen was chosen at the investigator's discretion. Option 1: trastuzumab 8 mg/kg via IV infusion on Day 1 of Cycle 1, then 6 mg/kg IV on Day 1 of each subsequent 3-week cycle; plus a minimum of 6 cycles with docetaxel 75 or 100 mg/m\\^2 IV on Day 1 of each 3-week cycle. Option 2: trastuzumab 4 mg/kg IV on Day 1 of Cycle 1, then 2 mg/kg IV weekly beginning on Day 8 of Cycle 1; plus a minimum of 18 weeks with paclitaxel 80 mg/m\\^2 IV weekly. Treatment continued until disease progression, unacceptable toxicity, or study termination. If trastuzumab or docetaxel were discontinued for toxicity, the other agent could be continued as monotherapy.","id":"OG000","title":"Trastuzumab + Taxane"},{"description":"Participants received trastuzumab emtansine plus pertuzumab-placebo. Trastuzumab emtansine was administered as 3.6 mg/kg via IV infusion, following completion of the placebo IV infusion, on Day 1 of each 3-week cycle. Treatment continued until disease progression, unacceptable toxicity, or study termination.","id":"OG001","title":"Trastuzumab Emtansine + Placebo"},{"description":"Participants received trastuzumab emtansine plus pertuzumab. Trastuzumab emtansine was administered as 3.6 mg/kg via IV infusion, following completion of the pertuzumab IV infusion, on Day 1 of each 3-week cycle. Pertuzumab was given as 840 mg IV on Day 1 of Cycle 1, then 420 mg IV on Day 1 of each subsequent 3-week cycle. Treatment continued until disease progression, unacceptable toxicity, or study termination.","id":"OG002","title":"Trastuzumab Emtansine + Pertuzumab"}],"paramType":"MEDIAN","populationDescription":"ITT Population (High HER2 mRNA Subpopulation).","reportingStatus":"POSTED","timeFrame":"Up to 70 months from randomization until clinical cutoff of 15-May-2016 (every 3 months until death, loss to follow-up, withdrawal, or study termination)","title":"OS at Clinical Cutoff Among Those With High HER2 mRNA Levels","type":"SECONDARY","unitOfMeasure":"months"}